In patients over the age of 60 years with acute myeloid leukemia (AML), treatment results are disappointing with only modest improvement over the last four decades. 1 In addition to the limited success rates after induction therapy, one major problem is that older adults have a high rate of relapse, and no clearly effective postremission therapy has been established. 2, 3 We recently reported the results of our randomized phase III AML HD98-B treatment trial. 4 In this study, we showed that the addition of all-trans retinoic acid (ATRA) to induction and first consolidation therapy significantly improved complete remission (CR) rates and survival in patients with AML (excluding acute promyelocytic leukemia (APL)) over the age of 60 years. The present report focuses on the second randomization of this trial that was performed to assess the role of a second intensive, intravenously (i.v.) given consolidation with idarubicin and etoposide versus a 1-year oral maintenance therapy with the same drugs.
Patients 61 years or older with de novo AML or refractory anemia with excess of blasts in transformation (RAEB-t) defined by the French-American-British (FAB) classification system, secondary AML (s-AML) with a preceding history of myelodysplasia, or therapy-related AML following treatment of primary malignant disease (t-AML) were eligible for entry into the trial. Patients with APL, patients with concomitant liver, renal or cardiac disease, and patients with a performance status WHO 42 were not included. The treatment schedule was as follows: after a first up-front randomization for the addition of ATRA to induction therapy with two cycles of ICE (idarubicin 12 mg/m 2 i.v. days 1 and 3, cytarabine 100 mg/m 2 cont. i.v. days 1-5, etoposide 100 mg i.v. days 1 and 3) and first consolidation therapy with HAM (cytarabine 0.5 g/m 2 /12 h i.v., days 1-3; mitoxantrone 10 mg/m 2 i.v., days 2 and 3), patients in CR were randomized to either second intensive consolidation therapy IEiv (idarubicin 12 mg/m 2 i.v. days 1 and 3, etoposide 100 mg/ m 2 i.v. days 1-5) or a 1-year oral maintenance therapy IEpo (idarubicin 5 mg p.o. days 1, 4, 7, 10, 13; etoposide 100 mg p.o. days 1 and 13; repeated on day 29 for 12 courses).
Between August 1997 and April 2003, 329 patients were recruited. After two cycles of induction therapy 151 of 329 eligible patients achieved CR (46%). First consolidation therapy with HAM or A-HAM was given in 119 patients. After first consolidation therapy, randomization between IEiv versus IEpo was intended. Causes for not proceeding to randomization were allogeneic transplantation from an HLA-identical sibling donor (n ¼ 7), no informed consent (n ¼ 14), and relapse in two patients after first consolidation therapy. Finally, 96 patients were randomized between IEiv (n ¼ 47) and IEpo (n ¼ 49). Table 1 shows the clinical parameters according to second randomization.
Of 47 patients randomized to IEiv, three withdrew informed consent and received no further therapy, and two patients relapsed before the start of IEiv. Forty-two patients received IEiv in median 55 days (range: 40-89 days) after first consolidation therapy with HAM or A-HAM. All patients were treated inhospital, and the median duration of hospital stay was 29 days (range, 7-42 days). All patients suffered from hematological toxicity with median times of neutropenia (neutrophils o0.5 Â 10 9 /l) and thrombocytopenia (platelets o20 Â 10 9 /l) of 13 (range, 1-27 days) and 7.5 days (range, 0-26 days), respectively. In 26 of 42 patients (62%), i.v. antibiotics were administered due to neutropenic fever (n ¼ 15), septicemia (n ¼ 4), pneumonia (n ¼ 4), and soft tissue infection (n ¼ 3). There was one death 12 days after start of IEiv due to pneumonia and subsequent septicemia.
Of 49 patients randomized to IEpo, three received intensive late consolidation (IEiv, n ¼ 2; HAM, n ¼ 1), and two patients relapsed before the start of IEpo. Forty-four patients received the first cycle of IEpo in median 55 days (range 25-268 days) after first consolidation therapy. A median of four cycles (range, one to 12) of IEpo were administered; eight patients completed 12 cycles of IEpo. Causes of premature termination of IEpo were relapse in 34 cases, persistent thrombocytopenia below 50 Â 10 9 /l after the forth cycle in one case, and infectious spondylitis after the second cycle in one case. A total of 251 cycles IEpo were administered. No hematological toxicity WHO grade III/IV was observed in patients who were in continuous CR. Four patients were admitted to the hospital due to fever (438.01C) and one due to infectious spondylitis, and all received i.v. antibiotics (11%). The median duration of their hospital stays was 6 days (range 3-9 days).
The median estimated follow-up time after second randomization was 52 months. Seventy-one of the 96 patients have died resulting in an estimated survival probability after 48 months of 24% (95 confidence interval, 17-36%). Of the 96 randomized patients, 80 relapsed, and one patient died during IEiv-induced cytopenia leading to a cumulative incidence of relapse (CIR) and death after 48 months of 82% (standard error, 0.04) and 1% (standard error, 0.01), respectively. Of the 80 relapsed patients, 39 received either no or palliative treatment. Following an intensive reinduction therapy, 13 of 41 (32%) patients achieved a second CR two of whom received an autologous and one an allogeneic stem cell transplantation. Analysis according to second randomization on an intention-to-treat basis revealed a statistically significant lower CIR (P ¼ 0.005) in patients assigned to IEiv compared to those assigned to IEpo. This translated into a statistically significant better survival (P ¼ 0.04) with estimated median survival times from second randomization of 22.3 and 14.3 months in the IEiv and the IEpo arm, respectively (Figure 1) .
The principle conclusion of the second randomization of the AML HD98-B trial is that a second intensive consolidation with idarubicin and etoposide resulted in lower CIR and superior survival compared to a mild p.o. maintenance therapy with the same drugs. Myelosuppression during the p.o. maintenance therapy with IEpo was mild or absent in the majority of patients. Therefore, one could argue that there was only a minor or no therapeutic effectiveness of IEpo. Even in this scenario, our study in elderly patients adds to previous knowledge, that is, that four cycles of intensive chemotherapy may be superior to only three cycles. 5 Additionally, our study highlights two problems of performing a randomization late during treatment course in elderly AML patients. On the one hand, only 29% of the initial patient cohort could be randomized after first consolidation therapy. Although this proportion is comparable to that of other recently published randomized studies addressing this issue, 6 ,7 the value of these results for the whole population is very limited. On the other hand, selection bias towards favorable risk factors is enormous.
Only two of 96 randomized patients where classified as high-risk according the Medical Research Council classification system. 8 This raises the question whether a stratification of elderly patients according to cytogenetics might be useful in the future to identify a population of patients who will benefit from longer 
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Figure 1
Survival according to second randomization.
Letters to the Editor
Preferential expression of a high number of ATP binding cassette transporters in both normal and leukemic CD34 þ CD38À cells In most cases of acute myeloid leukemia (AML) malignant stem cells are considered to be within the CD34 þ CD38À population. The involvement of CD34 þ CD38À cells in leukemogenesis is suggested by the presence of cytogenetically aberrant cells in the stem cell compartment in AML, as demonstrated by PCR and FISH for leukemia specific translocations. Furthermore, transplantation studies using NOD/SCID mice have shown that cells with leukemic engraftment and self renewal potential are exclusively found within the CD34 þ CD38À cell population and not in more differentiated CD34 þ CD38 þ populations. 1 Incomplete eradication of these primitive cells may eventually lead to disease relapse. Multidrug resistance induced by the expression of ATP binding cassette (ABC) transporters may hamper the eradication of these primitive leukemic cells.
ABC transporters represent the largest family of transmembrane proteins involved in the transport of a wide variety of substrates across biological membranes, including phospholipids, ions, peptides, steroids, polysaccharides, amino acids, organic anions, bile acids, drugs and other xenobiotics. Currently, the ABC superfamily consists of 48 members; that can be divided into seven subfamilies based on similarity in protein structure (ABCA, B, C, D, E, F and G). Some of these transporters (ABCB1, ABCC1 and ABCG2) are expressed at high levels on hematopoietic primitive cells. 2 The physiological function of ABC transporters in human stem cell biology is not well understood. A role for ABC transporters in the protection from genetic damage by naturally occurring xenobiotics has been suggested for hematopoietic stem cells. 3 This has recently been substantiated by the observation of increased sensitivity to xenobiotics in normal bone marrow cells in ABCB1 and ABCG2/BCRP knockout mice.
Recently, an increasing number of ABC transporters has been associated with extrusion of xenobiotic compounds and chemotherapeutical agents and thus may be important for stem cell protection. However, the expression pattern of many ABC transporters on hematopoietic CD34 þ CD38À cells is currently unknown. In AML overexpression of ABC transporters involved in drug resistance might represent an important mechanism of drug resistance. 2 We recently demonstrated similar expression and function of ABCG2 in CD34 þ CD38À cells in AML and normal bone marrow but observed significant mitoxantrone extrusion from these cells in the presence of ABCG2 inhibition, suggesting the presence of additional drug transporters in these cells.
We assessed gene expression profiles of normal primitive CD34 þ CD38À and more committed CD34 þ CD38 þ progenitor cells by quantitative real-time RT-PCR using micro fluidic cards, covering all 45 transmembrane ABC transporters. Highly enriched CD34 þ CD38À and CD34 þ CD38 þ cells (purity above 90%) were isolated by FACS sorting either from bone marrow (N ¼ 3) or from G-CSF stimulated peripheral blood collections (N ¼ 8).
GAPDH-normalized levels of ABC transporter gene expression in the CD34 þ CD38À cell fraction are shown in Figure 1a . Out of the 45 ABC transporters the expression of 36 ABC transporters was detectable in CD34 þ CD38À cells. Twenty ABC transporters were detectable in all 11 samples. The lower frequency of detection of the remaining 16 ABC transporters is probably due to the relatively low expression level of these genes which will be reflected in a binary answer of the PCR. 4 In line with this, genes with the highest expression level where detectable in all samples whereas genes with a lower expression showed a lower frequency.
The five ABC transporters with the highest levels of expression were ABCA2, ABCC1, ABCB2, ABCB7, and ABCB1, confirming the relatively high expression of known stem cell transporters ABCB1/MDR1 and ABCC1/MRP1. ABC transporter gene expression levels were not significantly different in G-CSF
